J Immunol. 2026 Nov 2;215(11):vkag300. doi: 10.1093/jimmun/vkag300.
ABSTRACT
The anthracycline chemotherapeutic drug doxorubicin and the well-known compound staurosporine (STS) have long been regarded as prototypical inducers of the nonlytic cell death pathway apoptosis, with doxorubicin serving as a standard experimental tool for studying caspase-9-dependent intrinsic apoptosis. We recently showed that STS induces PANoptosis, a distinct lytic cell death pathway initiated by innate immune sensors and driven by caspases and/or RIPKs through PANoptosome complexes. Here, we asked whether doxorubicin similarly induces lytic cell death. Using CRISPR-Cas9 technology, we developed caspase-9-deficient immortalized bone marrow-derived macrophages to circumvent the embryonic lethality associated with germline deletion of caspase-9. We found that doxorubicin induced dose- and time-dependent lytic cell death-PANoptosis-in a caspase-9-dependent manner. Together with our previous findings on STS and caspase-8, these data demonstrate that classical inducers of nonlytic apoptosis also drive lytic, inflammatory cell death (PANoptosis) in innate immune cells, specifically macrophages. We further show that caspase-9 is a key driver of PANoptosis in response to doxorubicin and is required for the activation of caspase-1, caspase-8, caspase-3/-7, and gasdermin E, which are hallmarks of PANoptosis. These findings establish a role for caspase-9 beyond canonical apoptosis and suggest that PANoptosis and the downstream inflammatory response may contribute to the biological effects previously attributed to apoptosis for doxorubicin as a chemotherapeutic agent and for caspase-9 in other cancer and inflammatory disease settings.
PMID:43038175 | DOI:10.1093/jimmun/vkag300